Gilead Sciences: A Core Buy In Biotech With Several Potential Value Drivers

Gilead Sciences: A Core Buy In Biotech With Several Potential Value Drivers


Shareholders in Gilead Sciences have apparently been disappointed time and again, with the stock chart reflecting Wall Street's impatience and inability to see past declining HCV revenues toward the bigger picture. The company has a strong NASH lineup, a market projected to grow in excess of $20 billion by 2025.



from Biotech News